Arrowhead Research (ARWR)– Great Technology, But is the Company Over-Promising on ARC-520?

Two billion people globally have been infected with hepatitis B (HBV), and approximately 350 million are chronic carriers, including approximately 750,000 persons in the US. Among the chronically infected, 15%.

Quick take on Geron’s Imetelstat abstract

Today we finally got a glimpse at the ongoing investigator sponsored study of Geron (GERN) imetelstat in myelofibrosis. We have previously discussed this program here. The abstract can be found.

Horizon Pharma continues cash burn and dilution

We last wrote on Horizon Pharma (NASDAQ: HZNP) following their FDA approval of RAYOS, but seems not much has changed. However, the stock has risen roughly 60% year to date.

MYGN – To Myriad Investors – Your Risks are MyRisk

Co-Author: Dr. Tro Kalayjian Myriad (NASDAQ:MYGN) is a molecular diagnostics company that focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests in the United.

RTRX – Notes on Retrophin’s PKAN program

August was a month full of news for Retrophin (RTRX): financing, PR on preclinical results of their PKAN candidate (RE-024), PR on agreement to negotiate a candidate for autism and.

VICL – Quick take on Vical’s Allovectin failure

(With Patrick Crutcher) Today Vical (NASDAQ: VICL) reported top-line data from a Phase III trial of Allovectin-7 (A7) in patients with advanced melanoma. As we predicted in this article, the.

BCRX – BioCryst – Entering The HAE Market

BioCryst announced on Monday July 22 the successful completion of a Phase I study on the safety and PK of BCX4161, a candidate for the treatment of Hereditary angioedema (HAE)..

Biotech IPO’s hot in the first half of 2013

(jointly with Jason Chew and Juan Pedro Rodriguez Serrate) To say biotech IPOs have been hot seems like an understatement. The past year has been an open feeding frenzy for.

EDAP – A look at microcap device maker, EDAP TMS

Last year, we had projected that EDAP TMS (NASDAQ:EDAP) would report data from their Phase 2/3 trial(ENLIGHT) trial for the indication of low risk, localized prostate cancer. However, we have.

SRPT – A Quick Look At The Chart

Sarepta Therapeutics, Inc - Nasdaq(SRPT) Quick update: A big drop in SRPT today leaving the traders with speculation that there could be a leak about the decision to file for accelerated.

DCTH – Soaring Ahead of The Upcoming Advisory Committee

Delcath Systems, Inc. (DCTH) -Nasdaq DCTH has been on our watch list for a while, looking for an entry point. we kept following out the stock performance at the forum and.

PPHM – Peregrine’s Bavituximab future looks bleak

We have previously discussed[1][2] the numerous shortcomings of the overhyped oncology developer, Peregrine Pharmaceuticals (NASDAQ: PPHM). With further details on a botched Phase II trial that still leave many questions,.

SGMO – Sangamo Getting Ahead Of Itself

SGMO: Sangamo Getting Ahead Of Itself Sangamo BioSciences has received a great deal of attention in recent weeks with the unveiling of a broad orphan drug therapy initiative at JPMorgan..

ZIOP – Preparing for an Explosive Move

ZIOPHARM Oncology, Inc. (ZIOP)-Nasdaq Since November 11, 2012 ZIOP was trading in a horizontal channel, the upper resistance line at $4.81 and the lower support line at $4.01, till February.

After Phase III failure, Celsion is still worthless

After much debate from bulls and bears, in late January, Celsion (NASDAQ: CLSN) reported that the Phase 3 HEAT study of ThermoDox failed to meet the primary endpoint of achieving at.

SRPT – Preparing For The Next Move

Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is a biotech company under the spotlights since early October 2012, after presenting strong Phase IIb results for the compound Eteplirsen in the treatment of.

The IBB and SPX In The Decision Zone

In my previous report “IBB – A Closer Look at the Market’s Direction” I tried to find out if the markets bottomed out after the technical correction in the indices.

ALNY – Alnylam falls behind competition

We have previously spoken about Alnylam Pharmaceuticals (NASDAQ: ALNY) legal troubles with Tekmira Pharmaceuticals, and successfully predicted they would settle. Today, we want to talk a bit about their current.

FOLD – Amicus approaches inflection point

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

CLDX – A Positive Divergence Case

Celldex Therapeutics, Inc. (CLDX)-Nasdaq CLDX’s chart is one of a kind and very easy to understand even by a novice chart technician. It has been repeating the same moves, creating.

IBB – A Closer Look at the Market’s Direction

In my previous report  “IBB – Nasdaq Biotechnology Index – Reaching a Critical Point ” I tried to find out if the technical correction in the index $IBB reached a.

ALNY – Troubled Legal Battle Ahead For Alnylam

With shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) up well over 150% year-to-date, with 52 week highs at $21.38, we began an investigation into their current valuation and pending catalysts. Alnylam.

THLD – More uncertainty ahead for Threshold

As we previously suggested, Threshold Pharmaceuticals (NASDAQ: THLD) had some question marks about their future prospects of TH-302 in two key indications: pancreatic cancer and soft-tissue sarcoma. Recent data readouts.

ACAD – The Last Run to The Parkinson’s Disease Psychosis Results

ACADIA Pharmaceuticals Inc. (ACAD) -NasdaqGM Catalyst: late Nov. P-III results for Parkinson disease Acadia reported a 100% patient enrollment on Sep 05th: ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase.

ISIS and AEGR – Where do they stand after the FDA Advisory Committee meetings?

October 17 and 18, 2012 saw back-to-back meetings of the FDA Endocrine and Metabolic Drugs Advisory Committee (EMDAC) to review pending new drug applications (NDAs) for two drugs for homozygous.

EXEL – Looking for Direction Ahead of the PDUFA date

Exelixis (NASDAQ: EXEL) On 5/30/12, Exelixis submitted their NDA for Cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). They were subsequently.

THLD – What’s left for Threshold

In the first part of the year, Threshold Pharmaceuticals (THLD) delivered considerable returns for investors with a partnership deal for TH-302 and “positive” top-line Phase II data in pancreatic cancer..

SRPT – Sarepta Presents 48-Week Data At World Muscle Society Congress

Sarepta Presents 48-Week Data At World Muscle Society Congress Long-term safety and efficacy results were presented this Saturday at the WMS Congress in Persh, Australia. We had already learned from.

PPHM – Little value in Peregrine Pharmaceuticals

For a very brief period of time, Peregrine Pharmaceuticals (NASDAQ: PPHM) had become the phoenix that rose from the ashes. Peregrine recently posted overall survival(OS) data from their randomized Phase.

VNDA – A quick review on Vanda’s tasimelteon

After our first quick take on Vanda Pharmaceuticals (NASDAQ: VNDA), we wanted to provide a deeper insight into the development of tasimelteon, the company’s dual MT1/MT2 melatonin receptors agonist. Vanda.

EXEL – In A Consolidation Mode

EXEL “Exelixis” had an impressive uptrend starting in June 2012, anticipating the FDA reply for the NDA filling & priority review, starting from the $4.40 area, reaching the $6.95 point.

Browsing 31 / 48 articles
    1 2